What do doctors typically charge for Injection Trastuzumab-anns Biosimilar Kanjinti 10 Mg?

The nationwide median physician charge for Injection Trastuzumab-anns Biosimilar Kanjinti 10 Mg (HCPCS Q5117) is $191.61. Doctor billed charges vary based on geographic region, setting, and overhead.

What is the standard insurance baseline for HCPCS Q5117?

The standard insurance baseline reimbursement rate is $26.64. This represents the customary allowable amount established across standard fee schedules.

Home/Procedures/Injection Trastuzumab-anns Biosimilar Kanjinti 10 Mg

HCPCS Q5117Medical Service

Injection Trastuzumab-anns Biosimilar Kanjinti 10 Mg

Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg. Clinical pricing breakdown and utilization metrics across 16 practicing doctors nationwide.

$191.61

Peer Median Charge

Gross billed rate

$26.64

Standard Baseline

Customary allowable

7.2x

National Markup

Charge vs baseline

Active Physicians

Billing this code

Planning care or already received a bill for CPT Q5117?Calculate total facility bundle costs or generate an assertive dispute settlement offer.

Calculate Bundled Cost →Dispute an Inflated Bill 🧾

Understanding This Medical Fee

Gross Charge vs Negotiated Payment: The median physician charge for this service is $191.61. However, insured patients almost never pay this full amount directly. Insurers negotiate rates down toward the $26.64 baseline.

Self-Pay & Uninsured Guidance: If you are paying without insurance or out-of-network, request a prompt-pay cash discount. Most medical practices are willing to settle self-pay bills near the customary baseline rate rather than the full gross charge.

Key Questions for Your Doctor's Billing Office:

"Does Dr. [Name] participate in my specific insurance plan network?"
"What is the total self-pay or cash rate for code Q5117 if paid upfront?"
"Are there separate facility, anesthesia, or pathology fees associated with this procedure?"